Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Is Soaring Today

By Prosper Junior Bakiny - Apr 26, 2021 at 2:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hint: It's not because of anything the company said or did.

What happened?

Shares of Sorrento Therapeutics (SRNE 6.97%) are rising sharply on Monday and were up by 10.8% as of 1:43 p.m. EDT after jumping by as much as 14.6% earlier in the trading session. The biopharmaceutical company did not report any news, but perhaps the market is responding to comments made by Mad Money host Jim Cramer regarding Sorrento Therapeutics on his show on Friday, April 23. 

So what

Jim Cramer's comments hardly painted a bullish picture of Sorrento Therapeutics. During the lightning round bell -- when he gives quick and short answers to callers' questions on various stocks -- Cramer said the following: "There'll be a news release and it'll spike 3-4 points ... and that'll give you a chance to get out." Note that Sorrento Therapeutics is a clinical-stage biopharmaceutical company with a rich pipeline that includes more than half a dozen coronavirus-related programs, among many others.

It wouldn't be surprising if some news concerning one of the company's pipeline candidates sent its stock price higher. However, if that happens, Cramer thinks it would provide a good opportunity for investors to "get out." This comment suggests that while Cramer believes there is some upside potential for the stock (which may help explain today's jump), he doesn't think Sorrento Therapeutics is a good long-term bet. 

Piggy bank wearing a face mask.

Image source: Getty Images.

Now what

For what it's worth, I am also of the opinion that Sorrento Therapeutics isn't a good pick, at least not for investors focused on the long game. Sure, the healthcare company does have a raft of pipeline candidates, and a couple of its COVID-19 diagnostic test kits have earned emergency use authorization.

But with most of its experimental treatments still in their early testing phases, Sorrento Therapeutics has a lot to prove. That is especially true considering its stock price has jumped by 229% in the past 12 months in part thanks to its coronavirus-related efforts. I wouldn't even consider initiating a position in Sorrento Therapeutics until the company produces more positive results from clinical trials, especially late-stage studies. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$2.15 (6.97%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.